The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorE-DA Hospital
About this trial
Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal biopsy protocol of BE.
Eligibility criteria
Qualifiers
Adults with columnar-lined esophagus
Disqualifiers
A prior history of endoscopic treatment for Barrett's Esophagus
A prior history of upper gastrointestinal malignancy
A prior history of total or subtotal gastrectomy
Esophageal varices noted during the procedure
Trial design
Treatments tested in this trial
- One biopsy
- Three biopsy
- Seattle protocol
- Endoscopy
Treatment groups
165 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov